Latest Industry Insights

We interview Raffaello Sbordoni, research scientist at Revivocell, to dive deeper into how high-complexity in vitromodels are supporting pharmaceutical development and their future potential.

At ELRIG’s Research & Innovation 2024 event, Technology Networks spoke to Dr. Véronique De Conto, project leader in in vitro pharmacology at HCS Pharma, to learn more about their powerful tools for in vitro metastasis propagation.

At the European Laboratory Research and Innovation Group’s (ELRIG) Research and Innovation 2024 event, we asked a selection of start-up companies in the biotech space the same question: what are the key challenges you currently face?

We spoke with Dr. Bryan Oronsky, chief development officer at EpicentRx, to discover more about the promise of multipurpose drugs and the potential of EpicentRx’s nibrozetone (RRx-001) for several conditions.

The industry's search for alternatives to traditional preclinical drug testing methods has led to a growing interest in the potential of three-dimensional (3D) in vitro models. To delve deeper into this subject, Technology Networks spoke with Madhu Lal-Nag, chief scientific officer at InSphero, a 3D in vitro model company with a mission to “modernize drug discovery in ways that inspire researchers everywhere to reach their full potential and fuel a new era of breakthrough therapies.”

In this interview, Dr. Mason tells us about her career path and experiences along the way, as well as sharing advice for women considering a career in science.

We spoke to Olivier Barberan, director of Translational Medicine Solutions at Elsevier, to find out more about how predictive tools can inform pharma companies and help pave the way for drugs to get to market.

Encouraging scientists to rethink the materials and methods they use will help to foster a culture of sustainability within research institutions and across various industries. Technology Networks spoke with Dr. Joel Eichmann from Green Elephant Biotech to learn more about the creation of its plant-based plastic labware, and his broader vision for embedding sustainability within the biotech industry.

To find out more about AI in pharma, Technology Networks spoke with Roger Palframan, head of US Research and digital for Early Solutions at UCB.

In this interview, Dr. Jason Park, co-founder and CEO of Empress Therapeutics, tells us more about the Chemilogics platform and the benefits this approach to drug discovery can offer.